PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26109805-0 2015 beta-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis. Propranolol 61-72 adrenoceptor beta 2 Homo sapiens 0-26 26109805-1 2015 AIM: To evaluate the association of beta-2 adrenergic receptor (beta2-AR) gene polymorphism with response of variceal pressure to propranolol in cirrhosis. Propranolol 130-141 adrenoceptor beta 2 Homo sapiens 36-62 26109805-1 2015 AIM: To evaluate the association of beta-2 adrenergic receptor (beta2-AR) gene polymorphism with response of variceal pressure to propranolol in cirrhosis. Propranolol 130-141 adrenoceptor beta 2 Homo sapiens 64-72 26109805-6 2015 CONCLUSION: The variceal pressure response to propranolol was associated with polymorphism of beta2-AR gene. Propranolol 46-57 adrenoceptor beta 2 Homo sapiens 94-102 24837703-11 2014 Consistently, in the presence of propranolol (10(-6)M), a beta-AR blocker, the arterenol (10(-8)M) effects on thymocytes were augmented. Propranolol 33-44 adrenoceptor beta 2 Homo sapiens 63-65 25026350-1 2014 CONTEXT: Propranolol, atenolol, and ICI118,551 are non-selective beta-adrenergic receptor (AR), beta1-AR, and beta2-AR antagonists, respectively. Propranolol 9-20 adrenoceptor beta 2 Homo sapiens 110-118 25523517-2 2015 The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Propranolol 16-27 adrenoceptor beta 2 Homo sapiens 47-55 25523517-2 2015 The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Propranolol 190-201 adrenoceptor beta 2 Homo sapiens 47-55 25323788-5 2014 The inflammatory-related cytokines interleukin (IL)-1beta, IL-6 and IL-8 were detected after pretreatment with the alpha1/beta2-AR blockers phentolamine/propranolol, both in vitro and in vivo. Propranolol 153-164 adrenoceptor beta 2 Homo sapiens 115-130 24933041-5 2014 In particular, the beta2-AR seems to be the mostly involved in these responses, and the beta1-/beta2-AR blocker propranolol results highly effective in inhibiting both the increase of VEGF expression caused by a hypoxic insult and the consequent neovascular response. Propranolol 112-123 adrenoceptor beta 2 Homo sapiens 95-103 22743651-3 2012 In a prior report, we identified expression of beta2-AR (B2-AR) and its phosphorylated form (B2-ARP) in a case of infantile hemangioma that responded to propranolol treatment. Propranolol 153-164 adrenoceptor beta 2 Homo sapiens 47-55 24905583-4 2014 NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA. Propranolol 163-174 adrenoceptor beta 2 Homo sapiens 72-80 24905583-4 2014 NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA. Propranolol 163-174 adrenoceptor beta 2 Homo sapiens 142-150 24905583-4 2014 NCI-H292 epithelial cell line was used to determine the contribution of beta2-AR signaling to CSE-induced MUC5AC production by treatment with beta2-AR antagonists propranolol and ICI118551 and beta2-AR-targeted small interfering RNA. Propranolol 163-174 adrenoceptor beta 2 Homo sapiens 142-150 24554803-5 2013 RESULTS: Results gained shows that following the blockade of beta-2 adrenergic receptor with Propranolol (20 mg-aerosol), stimulation of alpha adrenergic receptor with Oxedrine (120 mg-aerosol) and blockage of these receptors with Tolazoline (20 mg-aerosol), does not change significantly the bronchomotor tonus of the tracheobronchial tree (p > 0.1). Propranolol 93-104 adrenoceptor beta 2 Homo sapiens 61-87 24214595-5 2013 Adding of beta2AR antagonist propranolol to the Jurkat cells pre-incubated with isoproterenol didn"t change expression of IL-2. Propranolol 29-40 adrenoceptor beta 2 Homo sapiens 10-17 24214595-6 2013 beta2AR antagonist propranolol induced slight increase of IL-2 expression in PHA-stimulated Jurkat cells pre-incubated with isoproterenol. Propranolol 19-30 adrenoceptor beta 2 Homo sapiens 0-7 24214595-10 2013 Propranolol prevented increase of IL-10 expression in the PHA-stimulated Jurkat cells pre-incubated with beta2AR agonist. Propranolol 0-11 adrenoceptor beta 2 Homo sapiens 105-112 23186269-10 2012 The beta2AR blocker propranolol abrogated the growth inhibitory effect of formoterol. Propranolol 20-31 adrenoceptor beta 2 Homo sapiens 4-11 22743651-3 2012 In a prior report, we identified expression of beta2-AR (B2-AR) and its phosphorylated form (B2-ARP) in a case of infantile hemangioma that responded to propranolol treatment. Propranolol 153-164 adrenoceptor beta 2 Homo sapiens 57-62 18222471-5 2008 Receptor stability in detergent solution was studied by isothermal denaturation, and it was found that the E122W and E122Y mutations enhanced the beta(2)AR thermal half-life by 9.3- and 6.7-fold, respectively, at 37 degrees C. The beta(1)AR was also stabilized by the introduction of tryptophan at Glu147(3.41), and the effect on protein behavior was similar to the rescue of the unstable wild-type receptor by the antagonist propranolol. Propranolol 426-437 adrenoceptor beta 2 Homo sapiens 146-155 22133559-7 2012 A recent study showed that propranolol, a beta adrenergic receptor (beta-AR) antagonist, was effective as treatment for infantile hemangioma. Propranolol 27-38 adrenoceptor beta 2 Homo sapiens 68-75 16177222-5 2006 SR 59119A-induced relaxation was unaffected by the blockade of ADRB1 and ADRB2 by 0.1 microM propranolol but was significantly decreased by the blockade of ADRB1, ADRB2, and ADRB3 by 10 microM propranolol. Propranolol 193-204 adrenoceptor beta 2 Homo sapiens 163-168 15595859-7 2004 Zonal displacement chromatography using CGP 12177A as the marker and racemic mixtures of the antagonists nadolol and propranolol demonstrated that the immobilized beta(2)-AR retained its ability to specifically bind these compounds. Propranolol 117-128 adrenoceptor beta 2 Homo sapiens 163-173 16335946-3 2005 This inhibition was counteracted by addition of the beta(2)-AR antagonist propranolol (LZP). Propranolol 74-85 adrenoceptor beta 2 Homo sapiens 52-62 16374847-0 2006 Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Propranolol 89-100 adrenoceptor beta 2 Homo sapiens 13-39 16374847-3 2006 We hypothesized that gene polymorphisms at the beta2-AR may influence the hemodynamic response to propranolol in patients with cirrhosis. Propranolol 98-109 adrenoceptor beta 2 Homo sapiens 47-55 16082424-0 2005 Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Propranolol 85-95 adrenoceptor beta 2 Homo sapiens 71-76 16082424-4 2005 To examine the association between the Gln27Glu polymorphism of the ADRB2 gene and dyslipidemia induced by propranolol, we recruited 19 healthy individuals who were homozygous for either the Gln27 (wild-type, N = 11) or the Glu27 (homozygous mutant, N = 8) genotype. Propranolol 107-118 adrenoceptor beta 2 Homo sapiens 68-73 16082424-8 2005 Significant changes in physiological parameters (HR, SBP, DBP) have been found in association with ADRB2 variants in both native and mutant subgroups after propranolol intake. Propranolol 156-167 adrenoceptor beta 2 Homo sapiens 99-104 16082424-11 2005 The evidence that subjects homozygous for Gln27 in the ADRB2 gene show a significant reduction of HDL-CHO levels, as well as the increased TG levels in subjects homozygous for Glu27 after propranolol administration, suggest that the Gln27Glu polymorphism represents a risk factor for dyslipidemia induced by propranolol. Propranolol 308-319 adrenoceptor beta 2 Homo sapiens 55-60 12732361-5 2003 The non-selective beta(1)-/-beta(2)-AR antagonists; propranolol and CGP 12177, at 10(-7)M, inhibited luciferase activity induced by these agonists by 80-96%. Propranolol 52-63 adrenoceptor beta 2 Homo sapiens 28-38 15383152-10 2004 The enhancing effect of proatherogenic cytokine production by epinephrine was down regulated by the beta1 and beta2 adrenoceptor antagonist, propranolol, but not by the beta1 adrenoceptor antagonist, atenolol, suggesting the effect involved beta2 adrenoceptors. Propranolol 141-152 adrenoceptor beta 2 Homo sapiens 110-128 12642394-6 2003 Addition of the beta-AR antagonist, propranolol, blocked the ADR-induced alpha(2A)-AR desensitization. Propranolol 36-47 adrenoceptor beta 2 Homo sapiens 16-23 11159726-7 2001 The maximum extent of attenuation was RANTES > or = eotaxin > GM-CSF >> IL-8, and was prevented by either propranolol (1 microM), a non-selective beta-adrenoceptor antagonist, or ICI 118511 (IC(50) 15 nM), a selective beta(2)-adrenoceptor antagonist. Propranolol 118-129 adrenoceptor beta 2 Homo sapiens 230-250 12398570-8 2002 RESULTS: Compared with the ordinary dose of carvedilol 10 mg once a day, the improper regimen (10 mg after breakfast followed by 5 mg after lunch and dinner) increases the beta(2)-adrenoceptor binding occupancy at night (2300) to as high as the mean beta(2)-adrenoceptor binding occupancy after an ordinary dose of propranolol. Propranolol 315-326 adrenoceptor beta 2 Homo sapiens 172-192 9878881-14 1999 Blocking the sympathetic nervous system (SNS) transmission by application of the beta2-adrenoreceptor antagonist propranolol not only inhibited the increase but further downregulated the endotoxin induced IL-10 concentration in the media of whole blood cell cultures, whereas the TNF-alpha decrease was only partially prevented. Propranolol 113-124 adrenoceptor beta 2 Homo sapiens 81-101 9873044-9 1999 The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation. Propranolol 144-155 adrenoceptor beta 2 Homo sapiens 19-27 9873044-9 1999 The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation. Propranolol 144-155 adrenoceptor beta 2 Homo sapiens 100-108 9873044-9 1999 The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation. Propranolol 144-155 adrenoceptor beta 2 Homo sapiens 100-108 10408809-12 1999 Furthermore, application of the beta2-adrenoreceptor antagonist propranolol prevented the decrease of lymphocytes and diminished the neutrophilia. Propranolol 64-75 adrenoceptor beta 2 Homo sapiens 32-52 8392360-2 1993 A double-blind placebo-controlled study was conducted on the effects of oral terbutaline (beta 2-adrenoceptor agonist) and propranolol (beta 1 beta 2-adrenoceptor antagonist) on basal heat production of skeletal muscle, measured ex vivo by direct microcalorimetry. Propranolol 123-134 adrenoceptor beta 2 Homo sapiens 143-162 7476903-5 1995 Thus, the beta 2-adrenoceptor agonists albuterol and procaterol partially (approximately 40%) suppressed TNF-alpha generation in a propranolol-sensitive manner. Propranolol 131-142 adrenoceptor beta 2 Homo sapiens 10-29 9050006-12 1997 The beta-AR ligands isoprenaline and propranolol showed affinities expected for functional beta 2-ARs. Propranolol 37-48 adrenoceptor beta 2 Homo sapiens 4-11 7600375-6 1995 The potentiating effect of salbutamol on IgE production was blocked by two antagonists of beta 2-adrenoceptor, namely butoxamine and D,L-propranolol, suggesting a beta-adrenoceptor-mediated event. Propranolol 133-148 adrenoceptor beta 2 Homo sapiens 90-109 8101966-1 1993 We previously reported that Asn312 of the beta 2-adrenergic receptor and Asn385 in the homologous position in the 5-hydroxytryptamine1A receptor are important for binding to a class of beta-adrenergic receptor antagonists including propranolol and alprenolol. Propranolol 232-243 adrenoceptor beta 2 Homo sapiens 42-68 2169833-3 1990 We also studied the affinity of human lymphocyte beta 2-adrenoceptor for (+)-sotalol, (-)-sotalol, and (+/-)-propranolol. Propranolol 103-120 adrenoceptor beta 2 Homo sapiens 49-68 8157045-1 1993 A double blind placebo-controlled study was conducted of the effects of oral propranolol (beta 1 beta 2-adrenoceptor antagonist) and terbutaline (beta 2-adrenoceptor agonist) on erythrocyte heat production, measured by direct microcalorimetry under static conditions at 37 degrees C and pH 7.4. Propranolol 77-88 adrenoceptor beta 2 Homo sapiens 97-116 1845926-9 1991 The ability of propranolol but not atenolol to block this change suggests that the acute decrease in K+ levels was due to beta 2-adrenergic receptor stimulation. Propranolol 15-26 adrenoceptor beta 2 Homo sapiens 122-148 2169833-14 1990 The affinity of the human lymphocyte beta 2-adrenoceptor was approximately 60-fold greater for (-)-sotalol (Ki, 108 +/- 12 nM) than for (+)-sotalol (Ki, 6,410 +/- 1,020 nM), and approximately 20,000-fold greater for (+/-)-propranolol (Ki, 0.33 +/- 0.08 nM) than for (+)-sotalol. Propranolol 216-233 adrenoceptor beta 2 Homo sapiens 37-56 34417358-7 2021 We found that intra-dDG infusions of ISO given prior to retrieval caused deficits in working and reference memory which was blocked by pretreatment with the BAR-antagonist, propranolol (PRO). Propranolol 173-184 adrenoceptor beta 2 Homo sapiens 157-160 34650198-8 2021 RESULTS: In propranolol-treated HMC-1s, the expressions of ADRB1 (beta1-AR) and ADRB2 (beta2-AR) were reduced by 70% and 60%, respectively, and that of cytokines and mediators were reduced. Propranolol 12-23 adrenoceptor beta 2 Homo sapiens 80-85 34650198-10 2021 However, propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s. Propranolol 9-20 adrenoceptor beta 2 Homo sapiens 59-64 34650198-11 2021 CONCLUSIONS: Propranolol inhibit the proliferation of HemECs and promote their apoptosis and autophagy through acting on both beta1 and beta2 adrenoceptor in mast cell. Propranolol 13-24 adrenoceptor beta 2 Homo sapiens 136-154 34650198-14 2021 Propranolol can work well in shRNA-ADRB1 or shRNA-ADRB2 transfected HMC-1s. Propranolol 0-11 adrenoceptor beta 2 Homo sapiens 50-55 34417358-7 2021 We found that intra-dDG infusions of ISO given prior to retrieval caused deficits in working and reference memory which was blocked by pretreatment with the BAR-antagonist, propranolol (PRO). Propranolol 186-189 adrenoceptor beta 2 Homo sapiens 157-160 34638341-0 2021 Beta 2 Adrenergic Receptor Antagonist Propranolol and Opioidergic Receptor Antagonist Naltrexone Produce Synergistic Effects on Breast Cancer Growth Prevention by Acting on Cancer Cells and Immune Environment in a Preclinical Model of Breast Cancer. Propranolol 38-49 adrenoceptor beta 2 Homo sapiens 0-26 34309518-10 2021 Small skin arteries and arterioles, pre-treated with prazosin and stimulated with NE, exhibited ADRB2-mediated vasodilation, which was inhibited by the beta blockers, propranolol or timolol. Propranolol 167-178 adrenoceptor beta 2 Homo sapiens 96-101 2902891-9 1988 Similarly, in corresponding lymphocytes, only sotalol or propranolol increased beta 2-adrenoceptor density, while metoprolol and atenolol did not affect it and pindolol decreased it. Propranolol 57-68 adrenoceptor beta 2 Homo sapiens 79-98 35163250-3 2022 In the present study, we wanted to look deep into the effects of the ADRB2 blockers propranolol and ICI-118,551 on two main aspects of cancer progression: (i) the changes on the inflammatory response of ccRCC cells; and (ii) the modulation on the Warburg effect (glycolytic metabolism), concretely, on the expression of genes involved in the cell reactive oxygen species (ROS) balance and levels. Propranolol 84-95 adrenoceptor beta 2 Homo sapiens 69-74 2839668-5 1988 After propranolol administration, in vitro beta-1 and beta-2 adrenoceptor occupancy declined from initially 97% to less than 10% within 48 hr. Propranolol 6-17 adrenoceptor beta 2 Homo sapiens 54-73 2907348-3 1988 A more detailed analysis revealed that all beta-adrenoceptor antagonists increased right atrial beta 1-adrenoceptor density, but right atrial beta 2-adrenoceptor density was increased only in the sotalol/propranolol group, remaining unchanged in the metoprolol and atenolol groups, and was decreased in the pindolol group. Propranolol 204-215 adrenoceptor beta 2 Homo sapiens 142-161 2902891-7 1988 All beta-adrenoceptor antagonists increased right atrial beta 1-adrenoceptor density; on the other hand, only sotalol and propranolol also increased right atrial beta 2-adrenoceptor density, whereas metoprolol and atenolol did not affect it and pindolol decreased it. Propranolol 122-133 adrenoceptor beta 2 Homo sapiens 162-181 2873850-1 1986 A short-term effect of propranolol on beta 2-adrenoceptor density in mononuclear lymphocytes was studied in 15 male patients with essential hypertension. Propranolol 23-34 adrenoceptor beta 2 Homo sapiens 38-57 2885202-6 1987 Lymphocyte beta 2-adrenoceptor number increased significantly following propranolol treatment, but not after oxprenolol for atenolol. Propranolol 72-83 adrenoceptor beta 2 Homo sapiens 11-30 6849742-7 1983 6 The measurement of forearm blood flow following intravenous bolus injections of isoprenaline provides useful information about the beta 2-adrenoceptor antagonism of propranolol and practolol. Propranolol 167-178 adrenoceptor beta 2 Homo sapiens 133-152 2439825-5 1986 Propranolol treatment (4 X 40 mg/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; during treatment beta 2-adrenoceptor density remained elevated. Propranolol 0-11 adrenoceptor beta 2 Homo sapiens 63-82 2439825-6 1986 After withdrawal of propranolol, beta 2-adrenoceptor density declined slowly, being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h, though heart rate was significantly increased. Propranolol 20-31 adrenoceptor beta 2 Homo sapiens 33-52 2427860-2 1986 Propranolol (unselective; no ISA; 4 X 40 mg/day) increased beta 2-adrenoceptor density by 25-40%; after withdrawal beta 2-adrenoceptor density declined slowly, being still elevated for 3 days. Propranolol 0-11 adrenoceptor beta 2 Homo sapiens 59-78 2856815-3 1985 This effect appears to be mediated by beta 2-adrenoceptor stimulation, since the exercise-induced increase in beta 2-adrenoceptor density was markedly attenuated by pretreatment of the volunteers with propranolol (5 mg intravenously 45 min before exercise), but not by pretreatment with the beta 1-selective antagonist bisoprolol (2.5 mg intravenously 30 min before exercise). Propranolol 201-212 adrenoceptor beta 2 Homo sapiens 38-57 2856815-3 1985 This effect appears to be mediated by beta 2-adrenoceptor stimulation, since the exercise-induced increase in beta 2-adrenoceptor density was markedly attenuated by pretreatment of the volunteers with propranolol (5 mg intravenously 45 min before exercise), but not by pretreatment with the beta 1-selective antagonist bisoprolol (2.5 mg intravenously 30 min before exercise). Propranolol 201-212 adrenoceptor beta 2 Homo sapiens 110-129 6203844-4 1984 Propranolol, a competitive antagonist of beta 2-adrenergic receptor, blocks the inhibition of release and the cAMP accumulation caused by fenoterol. Propranolol 0-11 adrenoceptor beta 2 Homo sapiens 41-67 2875397-5 1986 The decrease in lymphocyte beta 2-adrenoceptor density induced by pindolol could be completely prevented by simultaneous administration of propranolol (3 X 40 mg/day) indicating that the PAA of pindolol is the cause of its beta-adrenoceptor decreasing effect. Propranolol 139-150 adrenoceptor beta 2 Homo sapiens 27-46 2439825-0 1986 Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. Propranolol 10-21 adrenoceptor beta 2 Homo sapiens 63-82 6134510-8 1983 Beta-blockers, particularly propranolol and metoprolol, with which we have the most experience, work via beta 2 adrenoceptor blockade in the heart. Propranolol 28-39 adrenoceptor beta 2 Homo sapiens 105-124 31296894-4 2019 Propranolol, a non-specific beta1-and beta2-adrenergic receptor antagonist, was recently designated as the first therapeutic (orphan) drug for VHL disease. Propranolol 0-11 adrenoceptor beta 2 Homo sapiens 38-63 33558238-7 2021 Our functional protein association networks analysis and knockdown of ADRB2 and AQP1 indicated that propranolol treatment and AQP1 down-regulation trigger the same pathway, suggesting that AQP1 is a major driver of beta-blocker antitumor response. Propranolol 100-111 adrenoceptor beta 2 Homo sapiens 70-75 16716-0 1977 Beta-2 adrenoceptor blocking activity of penbutolol and propranolol at very low doses. Propranolol 56-67 adrenoceptor beta 2 Homo sapiens 0-19 32854260-9 2020 In summary, propranolol and ICI-118,551 have shown antitumor benefits in VHL-derived ccRCC, and since ccRCCs comprise 63% of the total RCCs, targeting ADRB2 becomes a promising drug for VHL and other non-VHL tumors. Propranolol 12-23 adrenoceptor beta 2 Homo sapiens 151-156 31709066-4 2019 The method was applied to the human beta2-adrenergic receptor, resulting in eight room-temperature co-crystal structures with six different ligands, including previously unreported structures with carvedilol and propranolol. Propranolol 212-223 adrenoceptor beta 2 Homo sapiens 36-61 31624248-9 2019 These effects were reversed by the ADRB antagonists propranolol and ICI118,551 (an ADRB2-specific antagonist). Propranolol 52-63 adrenoceptor beta 2 Homo sapiens 83-88 30871232-2 2019 Yet even in tumors with active ADRB2 signaling propranolol may be ineffective. Propranolol 47-58 adrenoceptor beta 2 Homo sapiens 31-36 30871232-5 2019 Therefore, a comprehensive analysis of ADRB2 signaling in the context of other signaling mechanisms is necessary to identify patients who will benefit from propranolol therapy. Propranolol 156-167 adrenoceptor beta 2 Homo sapiens 39-44 30871232-6 2019 This review discusses how information on the antiapoptotic mechanisms activated by ADRB2 can guide clinical trials of ADRB2 antagonist propranolol as potential life-extending therapy for prostate cancer. Propranolol 135-146 adrenoceptor beta 2 Homo sapiens 83-88 30871232-6 2019 This review discusses how information on the antiapoptotic mechanisms activated by ADRB2 can guide clinical trials of ADRB2 antagonist propranolol as potential life-extending therapy for prostate cancer. Propranolol 135-146 adrenoceptor beta 2 Homo sapiens 118-123 30225948-1 2018 OBJECTIVE: A recent study observed a 2-fold greater risk of Parkinson disease (PD) in relation to the beta2-adrenoreceptor antagonist propranolol and a markedly lower risk of PD for the beta2-adrenoreceptor agonist salbutamol. Propranolol 134-145 adrenoceptor beta 2 Homo sapiens 102-122 30325031-4 2019 The order of Kb values between drugs such as adrenaline hydrochloride, norepinephrine bitartrate, and propranolol hydrochloride with beta2 -AR is well consistent with that reported in the literature. Propranolol 102-127 adrenoceptor beta 2 Homo sapiens 133-142 29515233-9 2018 We suggest that blocking beta2AR with propranolol or inhibiting FAK activation with PF562 271 may be novel strategies for depressed patients with invasive prostate cancer. Propranolol 38-49 adrenoceptor beta 2 Homo sapiens 25-32 28240622-2 2017 Propranolol, a nonselective beta1, beta2-adrenergic receptor antagonist, reduces resting heart rate and cardiac work caused by elevated circulating catecholamines. Propranolol 0-11 adrenoceptor beta 2 Homo sapiens 35-60 29472588-6 2018 We further show a clear role of both the cell membrane and the beta2-adrenoceptor in determining high local BY-propranolol concentrations at the cell surface. Propranolol 111-122 adrenoceptor beta 2 Homo sapiens 63-81 28721035-5 2017 beta2R antagonism by propranolol or ICI 118.551 (10-12-10-4 M) resulted in concentration-dependent inhibition of VI-induced cAMP production, and ICI 118.551 was more potent. Propranolol 21-32 adrenoceptor beta 2 Homo sapiens 0-6 26489037-0 2016 Influence of CYP2D6 and beta2-adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis. Propranolol 100-111 adrenoceptor beta 2 Homo sapiens 24-49 27133786-8 2016 The beta1-AR/beta2-AR inhibitor propranolol reduced the numbers of the neutrophils in the circulation, suppressed neutrophil infiltration into colonic tissues, and attenuated the colonic tissue damage promoted by chronic stress. Propranolol 32-43 adrenoceptor beta 2 Homo sapiens 13-21 27668163-1 2016 beta Blockers such as propranolol and labetalol are known to induce toxic myopathy because of their partial beta2 adrenoceptor agonistic effect. Propranolol 22-33 adrenoceptor beta 2 Homo sapiens 108-126 27035124-9 2016 Propranolol decreased beta2-adrenergic receptor-activated invasion. Propranolol 0-11 adrenoceptor beta 2 Homo sapiens 22-47 26489037-2 2016 This study is to evaluate the relationship between CYP2D6 and beta2-adrenergic receptor (beta2-AR) gene polymorphisms and the hemodynamic response to propranolol in Chinese Han patients. Propranolol 150-161 adrenoceptor beta 2 Homo sapiens 62-87 26489037-2 2016 This study is to evaluate the relationship between CYP2D6 and beta2-adrenergic receptor (beta2-AR) gene polymorphisms and the hemodynamic response to propranolol in Chinese Han patients. Propranolol 150-161 adrenoceptor beta 2 Homo sapiens 89-97 27094283-5 2016 Here, we present a standard computational protocol to evaluate the binding properties of the two enantiomers of the non-selective beta-blocker propanolol in the beta2 adrenergic receptor"s binding site. Propranolol 143-153 adrenoceptor beta 2 Homo sapiens 161-186 26574555-11 2016 We have thus demonstrated that propranolol acts on HemSCs in IH to suppress proliferation and promote apoptosis in a dose-dependent fashion via beta2AR perturbation, resulting in reduced cAMP and MAPK activation. Propranolol 31-42 adrenoceptor beta 2 Homo sapiens 144-151 26574555-9 2016 A selective beta2AR antagonist mirrored propranolol"s effects on HemSCs in a dose-dependent fashion, and a selective beta1AR antagonist had no effect, supporting a role for beta2AR signaling in IH pathobiology. Propranolol 40-51 adrenoceptor beta 2 Homo sapiens 12-19 26574555-16 2016 Furthermore, propranolol acts via perturbation of beta2AR, and not beta1AR, although both receptors are expressed in HemSCs. Propranolol 13-24 adrenoceptor beta 2 Homo sapiens 50-57 26058426-8 2015 Altogether these data suggest that beta2-AR plays an important role in prostate cancer metastasis formation and that the treatment with antagonist propanolol, could represents an interesting tool to control this process in cells overexpressing beta2AR. Propranolol 147-157 adrenoceptor beta 2 Homo sapiens 244-251